Evidence map›Paper›PMID 40694059›Full record

Trial reportDiabetologia2025

Early induction of insulin sensitisation treated by tirzepatide: a prospective, single-arm, open-label study in Japanese individuals with obesity and type 2 diabetes.

Yuko Yamaguchi, Hitoshi Kuwata, Masahiro Imura, Shota Moyama, Ryota Usui, Mari Matsushiro, Yoshiyuki Hamamoto, Yuichiro Yamada, Yutaka Seino, Yuji Yamazaki

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Diabetologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yuko Yamaguchi *Center for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan.ORCID http://orcid.org/0009-0001-8196-1406
Hitoshi Kuwata *Center for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan.
Masahiro ImuraCenter for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan.
Shota MoyamaCenter for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan.
Ryota UsuiCenter for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan.ORCID http://orcid.org/0000-0002-4641-0158
Mari MatsushiroCenter for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan.
Yoshiyuki HamamotoCenter for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan.ORCID http://orcid.org/0000-0002-1938-7394
Yuichiro YamadaCenter for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan.
Yutaka SeinoCenter for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan.ORCID http://orcid.org/0000-0002-1099-7989
Yuji YamazakiCenter for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan. yujiyamazaki1980@gmail.com.ORCID http://orcid.org/0009-0007-5876-8695

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aims/hypothesisThis study investigated insulin sensitivity using the hyperinsulinaemic-euglycaemic clamp technique in individuals with obesity and type 2 diabetes treated with tirzepatide at the low dose of 5 mg over a 12-week treatment period.

methodsThis prospective, single-arm, open-label, single-centre study was conducted in obese individuals with type 2 diabetes. Participants received tirzepatide 2.5 mg once weekly for 4 weeks; the dose was then increased to 5 mg for the remaining 8 weeks. The primary outcome was change in the glucose infusion rate. Secondary outcomes were changes in HbA

resultsSixteen participants completed the study. The GIR increased from 3.21 to 5.16 mg min CONCLUSIONS/

interpretationTirzepatide significantly improves insulin sensitivity within 12 weeks, indicating an early metabolic effect that is not solely attributable to weight loss.

trial registrationUMIN registration number: UMIN000056862.

Indexed as

Diabetes Mellitus, Type 2Hypoglycemic AgentsInsulinInsulin ResistanceObesityAdultAgedBlood GlucoseBody CompositionBody WeightEast Asian PeopleFemaleGlucose Clamp TechniqueGlycated HemoglobinHumansJapanBlood GlucoseGlycated HemoglobinHypoglycemic AgentsInsulinTirzepatideDual receptor agonistGIPInsulin sensitivityTirzepatideType 2 diabetes

Identifiers

PMID40694059

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.